Global Community

KITZ makes a bold move into the heart of the chipmaking supply chain by buying VTEX, turning it into a serious second-choice supplier for equipment makers that want an alternative to the dominant player. The deal is timed when the industry is coming off a lull, so a rebound in chip-factory spending could make this shift look bigger than the market expects.Read more

MindWalk Holdings Corp. (NASDAQ: HYFT) presents a classic case of market mispricing driven by a transitional lag.Read more

A healthcare device maker looks like a steady long-term add for someone trying to spread risk beyond big drug companies, helped by a recent buyout that broadens its brain-related tech offerings. The appeal is slow-and-steady growth and a long history of raising its payout, though the outlook isn’t flashy and some experts sound cautious.Read more

Novo Nordisk has gone from a steady insulin business to one of the key players behind the new wave of weight-loss and diabetes medicines, and the market may be overlooking how durable that shift is. Even with near-term pressure from pricing talks and production limits, wider insurance coverage, new product launches, and a deep pipeline could keep demand growing for years.Read more

Nova Ljubljanska Banka is aiming to grow its steady income and profits over the next few years, helped by tighter cost control and a plan to expand through deals. The big question is whether it can keep lending profits strong and navigate regional politics as it looks to deepen its presence in Croatia.Read more

Palantir aims to become the “control center” that helps governments and heavily regulated businesses put AI into real, security‑tight day‑to‑day work. The big question is whether its deep ties and hard‑to‑replace systems can outweigh government spending swings and tough competition from the largest cloud companies.Read more

Cboe Global Markets just posted standout results, and the business looks like it’s getting stronger across options, global markets, currency trading, and market data. The bigger question is whether the stock price reflects how steady and defensible this exchange business can be, or if investors are still pricing it like a much riskier company.Read more

I have been an investor in PRCT since before IPO. The wild fluctuations in share price recently make no sense.Read more

A new needle-free option for severe allergy treatment starts to break the long-standing grip of the familiar injector, and the market treats it like a losing fight between two newcomers. The more interesting angle is that both newcomers could grow the whole category by winning over people who avoid needles—if they can navigate insurance gatekeepers and a fast-approaching head‑to‑head launch.Read more